NCT06599086 Efficacy of Steroid Injection in Patients With Bifid Median Nerve Diagnosed Carpal Tunnel Syndrome
| NCT ID | NCT06599086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunus Burak Bayır |
| Condition | Carpal Tunnel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-09-15 |
| Primary Completion | 2025-09-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-09-15 with a primary completion date of 2025-09-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Various median nerve anatomical variations have been reported in the literature.One of these is the bifid median nerve.Due to its relatively higher cross-sectional area, it can facilitate compression of the median nerve in the carpal tunnel.Therefore, bifid median nerve is relatively common in patients with CTS.Some studies have shown that the bifid median nerve has an effect on surgical failure in the treatment of carpal tunnel syndrome.Apart from surgical treatment, perineural injection with corticosteroids is a treatment method that has been used for a long time in the treatment of mild and moderate carpal tunnel syndrome.It is controversial whether bifid median nerve has a negative effect on treatment effectiveness.When looking at the literature, there is no previous study on this subject.With the introduction of ultrasound into our daily practice, the frequency of ultrasound-guided perineural injections has increased.Ultrasound allowed us to see variations in the median nerve before injection.The aim of the study is to compare the effectiveness of steroid injection in patients with CTS with bifid median nerve and patients with CTS with non-variant median nerve.It is also to investigate whether this anatomical variation has a negative effect on the treatment.
Eligibility Criteria
Inclusion Criteria: * Being between the ages of 18-65 * Being clinically diagnosed with Carpal Tunnel Syndrome * Confirmation of mild and moderate Carpal Tunnel Syndrome diagnosis with EMG * Diagnosis of bifid median nerve after ultrasound evaluation, No variation was detected for the control group either. * Having typical Carpal Tunnel Syndrome symptoms for at least 3 months Exclusion Criteria: * History of polyneuropathy, brachial plexopathy, thoracic outlet syndrome, or wrist surgery * History of Inflammatory arthritis, hypothyroidism, pregnancy,rheumatological disorders or heart battery * current warfarin use, Prior steroid injection for CTS, trauma or neoplasm at the injection site, hypersensitivity to corticosteroids or skin infection at the injection site * other median nerve variations and presence of persistent median artery.
Contact & Investigator
Ayşegül Yaman, specialist
STUDY CHAIR
Ankara Etlik City Hospital
Frequently Asked Questions
Who can join the NCT06599086 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Carpal Tunnel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06599086 currently recruiting?
Yes, NCT06599086 is actively recruiting participants. Contact the research team at yunusburakbayir@gmail.com for enrollment information.
Where is the NCT06599086 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06599086 clinical trial?
NCT06599086 is sponsored by Yunus Burak Bayır. The principal investigator is Ayşegül Yaman, specialist at Ankara Etlik City Hospital. The trial plans to enroll 40 participants.